NIST Organizers: Sheng Lin-Gibson, Sumona Sarkar, Clare Allocca
FDA Organizers: Judith A. Arcidiacono, Steven S. Oh, Steven Bauer
NIST and FDA are actively collaborating on projects that address regulatory and measurement challenges for regenerative medicine products and advanced therapies. These collaborations leverage NIST expertise in measurement sciences to address specific analytical scientific challenges as well as FDA regulatory science, research and review expertise in regenerative medicine products to ensure that the science and standards developed address significant regulatory challenges that recur across the field. One of the fundamental challenges for manufacturers of regenerative medicine products is the counting of cells for manufacturing and dosing purposes. This workshop will focus on approaches for selecting appropriate cell counting methods and overcoming gaps in obtaining sufficient measurement assurance for cell counting. The expected outcome of the workshop is a Workshop Summary/Whitepaper to be published in a peer reviewed journal as well as input into standards for cell characterization.
The maximum capacity of this workshop is 50 persons. Meeting participants are expected to actively contribute to the discussions (see Requirements for Meeting Participation). Spaces for meeting observers will be allotted based on availability. This one-day public workshop will be followed by the meetings of the US TAG to ISO/TC 276: Biotechnology.
Agenda, Final Participation List, and Presentations
Final Participation List (View PDF)
8:30-9:00am Registration (West Square, NIST)
Breakfast (NIST Cafeteria)
9:00-9:30am
Welcome remarks NIST Sheng Lin-Gibson (10 min) presentation (View PDF)
Welcome remarks FDA Judith A. Arcidiacono (10 min) presentation (View PDF)
Cell counting overview Sumona Sarkar (10 min) presentation (View PDF)
9:30-11:45am (w/15 min break) Moderator: Judy Arcidiacono (FDA)
Session 1: Users’ forum - cell counting design and validation (30 min each):
Case study 1 Celgene: Michelle McLaughlin presentation (View PDF)
Case study 2 CDI: Wen Bo Wang presentation (View PDF)
Case study 3 Lonza: Joseph Finny
Case study 4 Memorial Sloan Kettering: Brigitte Senechal presentation (View PDF)
11:45am –12:30pm
Round Table discussion
12:30-1:30pm Lunch (on your own, NIST Cafeteria)
1:30-2:45 pm Moderator: Steve Bauer (FDA)
Session 2: Device provider’s forum: Precompetitive Considerations (15 min each):
Points to consider when establishing a cell counting measurement for the intended
purpose
Perspective on major challenges facing cell counting and recommendations
Presentation 1 Beckman Coulter: Lena Lee presentation (View PDF)
Presentation 2 Chemometec: Matthew Riolo presentation (View PDF)
Presentation 3 Fisher Scientific: Mike O'Grady presentation (View PDF)
Presentation 4 Nexcelom: Jean Qiu presentation (View PDF)
Presentation 5 Ovizio: Philip Mathuis presentation (View PDF)
2:45-3:00pm Coffee Break (on your own, NIST Cafeteria)
3:00-4:45pm Moderator: Sumona Sarkar presentation (View PDF)
Session 3: Approaches to overcoming gaps in obtaining sufficient measurement assurance for cell counting
Regulatory considerations for cell counting Steve Bauer / FDA (15 min) presentation (View PDF)
Measurement assurance strategies John Elliott/NIST (15 min) presentation (View PDF)
Round Table Discussion
4:45-5:30pm Session 4: Next steps Moderator: Sheng Lin-Gibson presentation (View PDF)
5:30 pm Meeting adjourned